ZIF-8@Pt Nanozyme Used for Scavenging Reactive Oxygen Species in the Treatment of Rheumatoid Arthritis

LEI Xuelan, QIU li, DU Fangxue

Abstract

To formulate a ZIF-8 nano mimetic enzyme conjugated with platinum metal (ZIF-8@Pt) that can scavenge reactive oxygen species (ROS) and to explore its potential applications in the treatment of rheumatoid arthritis (RA).
Methods The ZIF-8@Pt nanozyme was created by in situ reduction. Characterization of the nanozyme was then performed and its ability to mimic enzymes was investigated. Cell experiments were conducted using RAW264.7 cells, which were divided into three groups, including the untreated group (UT), the positive control group receiving lipopolysaccharide (LPS), which was designated as the LPS group, and the ZIF-8@Pt group receiving ZIF-8@Pt and LPS treatment. The cell experiments were conducted to evaluate the anti-inflammatory properties of ZIF-8@Pt through scavenging intracellular ROS. On the other hand, a collagen-induced arthritis (CIA) model was induced in rats. Similar to the group designations in the cell experiments, the rats were assigned to three groups, including a healthy control group (the UT group), a positive control group receiving a local injection of PBS solution in the knee joint, which was referred to as the control group, and a treatment group receiving a local injection of ZIF-8@Pt solution in the knee joint, which was referred to as the ZIF-8@Pt group. General evaluation, imaging observation, assessment of inflammatory factors, and pathological evaluation were performed to assess the therapeutic efficacy of ZIF-8@Pt against RA.
Results The in vitro experiment revealed significant difference in the levels of intracellular ROS and LPS-induced M1-type macrophage polarization between the LPS group and the ZIF-8@Pt group (P<0.05). The in vivo experiment showed that significant difference in the levels of inflammatory factors, including interleukin-1β (IL-1β), C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), and arginase-1 (Arg-1) in the knee joints of the CIA rats between the LPS group and the ZIF-8@Pt group (P<0.05). Comparing the findings for the ZIF-8@Pt group and the control group, pathology assessment revealed that ZIF-8@Pt reduced local hypoxia and suppressed osteoclastic activity, neovascularization, and M1-type macrophage polarization (P<0.05).
Conclusion The ZIF-8@Pt enzyme mimetic inhibits macrophage inflammatory polarization by ROS scavenging, thereby improving inflammation in RA. Furthermore, the ZIF-8@Pt nanozyme improves the hypoxic environment and inhibits angiogenesis and bone destruction, demonstrating promising therapeutic efficacy for RA.

 

Keywords: Nanomaterials, Nanozyme, Rheumatoid arthritis, Reactive oxygen species, Anti-inflammatory treatment

 

Full Text:

PDF


References


KUROWSKA-STOLARSKA M, ALIVERNINI S. Synovial tissue macrophages in joint homeostasis, rheumatoid arthritis and disease remission. Nat Rev Rheumatol, 2022, 18(7): 384–397. doi: 10.1038/s41584-022-00790-8.

LIU H, ZHU Y, GAO Y, et al. NR1D1 modulates synovial inflammation and bone destruction in rheumatoid arthritis. Cell Death Dis, 2020, 11(2): 129. doi: 10.1038/s41419-020-2314-6.

HUMBY F, LEWIS M, RAMAMOORTHI N, et al. Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Ann Rheum Dis, 2019, 78(6): 761–772. doi: 10.1136/annrheumdis-2018-214539.

LI W, SONG Y, LIANG X, et al. Mutual-reinforcing sonodynamic therapy against rheumatoid arthritis based on sparfloxacin sonosensitizer doped concave-cubic rhodium nanozyme. Biomaterials, 2021, 276: 121063. doi: 10.1016/j.biomaterials.2021.121063.

CHEUNG E C, VOUSDEN K H. The role of ROS in tumour development and progression. Nat Rev Cancer, 2022, 22(5): 280–297. doi: 10.1038/s41568-021-00435-0.

HERB M, SCHRAMM M. Functions of ROS in macrophages and antimicrobial immunity. Antioxidants (Basel), 2021, 10(2): 313. doi: 10. 3390/antiox10020313.

JOSHI-BARR S, De GRACIA LUX C, MAHMOUD E, et al. Exploiting oxidative microenvironments in the body as triggers for drug delivery systems. Antioxid Redox Signal, 2014, 21(5): 730–754. doi: 10.1089/ars. 2013.5754.

SHANG Z Z, QIN D Y, LI Q M, et al. Dendrobium huoshanense stem polysaccharide ameliorates rheumatoid arthritis in mice via inhibition of inflammatory signaling pathways. Carbohydr Polym, 2021, 258: 117657. doi: 10.1016/j.carbpol.2021.117657.

BARTOK B, FIRESTEIN G S. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev, 2010, 233(1): 233–255. doi: 10.1111/j.0105-2896.2009.00859.x.

YANG Y, GUO L, WANG Z, et al. Targeted silver nanoparticles for rheumatoid arthritis therapy via macrophage apoptosis and re-polarization. Biomaterials, 2021, 264: 120390. doi: 10.1016/j.biomaterials. 2020.120390.

TANG Q, CUI J, TIAN Z, et al. Oxygen and indocyanine green loaded phase-transition nanoparticle-mediated photo-sonodynamic cytotoxic effects on rheumatoid arthritis fibroblast-like synoviocytes. Int J Nanomedicine, 2017, 12: 381–393. doi: 10.2147/IJN.S120902.

RENDRA E, RIABOV V, MOSSEL D M. Reactive oxygen species (ROS) in macrophage activation and function in diabetes. Immunobiology, 2019, 224(2): 242–253. doi: 10.1016/j.imbio.2018.11.010.

CHAUHAN K, JANDU J S, BRENT L H, et al. Rheumatoid Arthritis. StatPearls. Treasure Island (FL): StatPearls Publishing, 2024.

LI X, WANG H, ZOU X, et al. Methotrexate-loaded folic acid of solid-phase synthesis conjugated gold nanoparticles targeted treatment for rheumatoid arthritis. Eur J Pharm Sci, 2022, 170: 106101. doi: 10.1016/j. ejps.2021.106101.

XU D, WU L, YAO H, et al. Catalase-like nanozymes: classification, catalytic mechanisms, and their applications. Small, 2022, 18(37): 2203400. doi: 10.1002/smll.202203400.

KIM J, KIM H Y, SONG S Y, et al. Synergistic oxygen generation and reactive oxygen species scavenging by manganese ferrite/ceria co-decorated nanoparticles for rheumatoid arthritis treatment. ACS Nano, 2019, 13(3): 3206–3217. doi: 10.1021/acsnano.8b08785.

TAMURA T, HIGUCHI Y, KITAMURA H, et al. Novel hyaluronic acid–methotrexate conjugate suppresses joint inflammation in the rat knee: efficacy and safety evaluation in two rat arthritis models. Arthritis Res Ther, 2016, 18(1): 79. doi: 10.1186/s13075-016-0971-8.

LU Y, STINNETTE T W, WESTRICK E, et al. Treatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate. Arthritis Res Ther, 2011, 13(2): R56. doi: 10.1186/ar3304.

WANG L, ZHU B, HUANG J, et al. Ultrasound-targeted microbubble destruction augmented synergistic therapy of rheumatoid arthritis via targeted liposomes. J Mater Chem B, 2020, 8(24): 5245–5256. doi: 10. 1039/D0TB00430H.

ZHU W, SUN X, ZHU L, et al. A novel BLyS peptibody down-regulates b cell and t helper cell subsets in vivo and ameliorates collagen-induced arthritis. Inflammation, 2016, 39(2): 839–848. doi: 10.1007/s10753-016-0314-6.

ROSS E A, DEVITT A, JOHNSON J R. Macrophages: the good, the bad, and the gluttony. Front Immunol, 2021, 12. doi: 10.3389/fimmu.2021. 708186.

CUTOLO M, CAMPITIELLO R, GOTELLI E, et al. The role of M1/M2 macrophage polarization in rheumatoid arthritis synovitis. Front Immunol, 2022, 13: 867260. doi:10.3389/fimmu.2022.867260.

MCINNES I B, SCHETT G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet, 2017, 389(10086): 2328–2337. doi: 10.1016/S0140-6736(17)31472-1.

HOSHINO-NEGISHI K, OHKURO M, NAKATANI T, et al. Role of anti-fractalkine antibody in suppression of joint destruction by inhibiting migration of osteoclast precursors to the synovium in experimental arthritis. Arthritis Rheumatol, 2019, 71(2): 222–231. doi: 10.1002/art. 40688.

KOMATSU N, TAKAYANAGI H. Mechanisms of joint destruction in rheumatoid arthritis--immune cell-fibroblast-bone interactions. Nat Rev Rheumatol, 2022, 18(7): 415–429. doi: 10.1038/s41584-022-00793-5.

MURATA K, FANG C, TERAO C. Hypoxia-sensitive COMMD1 integrates signaling and cellular metabolism in human macrophages and suppresses osteoclastogenesis. Immunity, 2017, 47(1): 66–79. e5. doi:10.1016/j.immuni.2017.06.018.

DOI K, MURATA K, ITO S, et al. Role of lysine-specific demethylase 1 in metabolically integrating osteoclast differentiation and inflammatory bone resorption through hypoxia-inducible factor 1α and E2F1. Arthritis Rheumatol, 2022, 74(6): 948–960. doi: 10.1002/art.42074.

LIU H, LI Y, SUN S, et al. Catalytically potent and selective clusterzymes for modulation of neuroinflammation through single-atom substitutions. Nat Commun, 2021, 12(1): 114. doi: 10.1038/s41467-020-20275-0.

KANDUKURI S S, NOOR A, RANJINI S S, et al. Purification and characterization of catalase from sprouted black gram (Vigna mungo) seeds. J Chromatogr B Analyt Technol Biomed Life Sci, 2012, 889-890: 50–54. doi: 10.1016/j.jchromb.2012.01.029.

ZHANG Z, YANG J, MIN Q, et al. Holo-lactoferrin modified liposome for relieving tumor hypoxia and enhancing radiochemotherapy of cancer. Small, 2019, 15(6): 1803703. doi: 10.1002/smll.201803703.

SHI C, LI M, ZHANG Z, et al. Catalase-based liposomal for reversing immunosuppressive tumor microenvironment and enhanced cancer chemo-photodynamic therapy. Biomaterials, 2020, 233: 119755. doi: 10. 1016/j.biomaterials.2020.119755.


Refbacks

  • There are currently no refbacks.